<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        63-19-10
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2010
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        DAIVOBET GEL
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        BETAMETHASONE DIPROPIONATE,Calcipotriol
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        500,50
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        µg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Topical
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Gel
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        30
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        1
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Tube
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        NCE
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        36
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        74.15
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="Leo Laboratories Limited" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            Leo Laboratories Limited
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 583]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            ALNAGHI COMPANY
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            Leo Pharma
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        D05AX02
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Daivobet&reg; is used as topical treatment of scalp psoriasis in<br />adults and on the skin of other body areas to treat mild to<br />moderate plaque psoriasis (psoriasis vulgaris) in adults.<br />Psoriasis is caused by your skin cells being produced too quickly.<br />This causes redness, scaling and thickness of your skin.</p><p><br />Daivobet&reg; contains calcipotriol and betamethasone.<br />Calcipotriol helps to bring the rate of skin cell growth back to<br />normal and betamethasone acts to reduce inflammation.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><u><strong>Do not use Daivobet&reg;</strong></u><br />&bull; If you are allergic (hypersensitive) to calcipotriol,<br />betamethasone or any of the other ingredients of Daivobet&reg;<br />&bull; If you have problems with calcium levels in your body (ask<br />your doctor)<br />&bull; If you have certain types of psoriasis: these are erythrodermic,<br />exfoliative and pustular (ask your doctor).<br />As Daivobet&reg; contains a strong steroid do NOT use it on skin<br />affected by<br />&bull; infections caused by viruses (e.g. cold sores or chicken pox)<br />&bull; infections caused by a fungus (e.g. athlete&rsquo;s foot or ringworm)<br />&bull; infections caused by bacteria<br />&bull; infections caused by parasites (e.g. scabies)<br />&bull; tuberculosis (TB) or syphilis<br />&bull; perioral dermatitis (red rash around the mouth)<br />&bull; thin skin, easily damaged veins, stretch marks<br />&bull; ichthyosis (dry skin with fish-like scales)<br />&bull; acne (pimples)<br />&bull; rosacea (severe flushing or redness of the skin on the face)<br />&bull; ulcers or broken skin<br />&bull; itching of the anus (back passage) or genitals (sex organs).<br /><u><strong>Take special care with Daivobet&reg;</strong></u><br />Before using this medicine, tell your doctor/nurse/ pharmacist<br />if<br />&bull; you are using other medicines that contain corticosteroids<br />as you may get side-effects<br />&bull; you have used this medicine for a long time and plan to stop<br />(as there is a risk your psoriasis will get worse or &lsquo;flare up&rsquo;<br />when steroids are stopped suddenly)<br />&bull; you have diabetes mellitus (diabetes) as your blood sugar/<br />glucose level may be affected by the steroid<br />&bull; your skin becomes infected as you may need to stop your<br />treatment<br />&bull; you have a certain type of psoriasis called guttate psoriasis<br />&bull; you have serious liver or kidney disease.<br /><u><strong>Special precautions</strong></u><br />&bull; Avoid use on more than 30 % of your body or using more than<br />15 grams per day<br />&bull; Avoid using under a batching cap, bandages or dressings as<br />it increases the absorption of the steroid<br />&bull; Avoid use on large areas of damaged skin or skin folds<br />(groin, armpits, under breasts) as it increases the absorption<br />of the steroid<br />&bull; Avoid use on your face or genitals (sex organs) as they are<br />very sensitive to steroids<br />&bull; Avoid excessive sunbathing, excessive use of solarium and<br />other forms of light treatment.<br /><u><strong>Children</strong></u><br />Daivobet&reg; is not recommended for the use in children below<br />the age of 18 years.<br /><u><strong>Taking other medicines</strong></u><br />Please tell your doctor or pharmacist if you are taking or have<br />recently taken any other medicines, including medicines<br />obtained without a prescription.<br /><u><strong>Pregnancy and breast-feeding</strong></u><br />Do not use Daivobet&reg; if you are pregnant (or might be pregnant)<br />or if you are breast-feeding, unless you have agreed it with your<br />doctor first. If your doctor has agreed that you can breast-feed,<br />take care and do not apply Daivobet&reg; to the breast area.<br />Ask your doctor or pharmacist for advice before taking any<br />medicine.<br /><u><strong>Driving and using machines</strong></u><br />This medicine should not have any effect on your ability to drive<br />or use machines.<br /><u><strong>Important information about some of the ingredients of<br />Daivobet&reg;</strong></u><br />Daivobet&reg; contains butylated hydroxytoluene (E321), which may<br />cause local skin reactions (e.g. contact dermatitis), or irritation<br />to the eyes and mucous membranes.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Always use Daivobet&reg; exactly as your doctor has told you. You<br />should check with your doctor or pharmacist if you are not sure.<br />How to put on Daivobet&reg;: Cutaneous use.<br /><u><strong>Instructions for proper use</strong></u><br />&bull; Use only on your psoriasis and do not use on skin which does<br />not have psoriasis<br />&bull; Shake the bottle before use and remove the cap<br />&bull; Squeeze the gel onto a clean finger or directly onto the area<br />affected by psoriasis.<br />&bull; Apply Daivobet&reg; to the affected area with your fingertips,<br />and rub it in gently until the area affected by psoriasis is<br />covered by a thin layer of gel.<br />&bull; Do not bandage, tightly cover or wrap the treated skin area<br />&bull; Wash your hands well after using Daivobet&reg;. This will avoid<br />accidentally spreading the gel to other parts of your body<br />(especially the face, mouth and eyes)<br />&bull; Do not worry if some gel accidentally gets on normal skin<br />near your psoriasis, but wipe it off if it spreads too far<br />&bull; In order to achieve optimal effect, it is recommended not to<br />take a shower or bath immediately after application of<br />Daivobet&reg; gel<br />&bull; After applying the gel, avoid contact with textiles which are<br />easily stained by grease (e.g. silk).<br /><u><strong>If you have scalp psoriasis</strong></u><br />&bull; Before applying Daivobet&reg; to the scalp, comb the hair to<br />remove any loose scales. Tilt your head to make sure<br />Daivobet&reg; does not run onto your face. It may help to part<br />your hair before you use Daivobet&reg;. Apply Daivobet&reg; to the<br />affected area with your fingertips, and rub it in gently<br />&bull; For treatment of the scalp usually an amount between 1 g and<br />4 g per day is sufficient (4 g corresponds to one teaspoon)<br />&bull; Washing your hair before application of Daivobet&reg; is not<br />necessary<br />&bull; In order to achieve optimal effect, it is recommended that the<br />hair is not washed immediately after application of Daivobet&reg;.<br />Let Daivobet&reg; remain on the scalp during the night or during<br />the day.<br /><u><strong>Duration of treatment</strong></u><br />&bull; Use the gel once a day. It may be more convenient to use the<br />gel in the evening<br />&bull; The normal initial treatment period is 4 weeks for scalp areas<br />and 8 weeks for non-scalp areas<br />&bull; Your doctor may decide on a different treatment period<br />&bull; Your doctor may decide on repeated treatment<br />&bull; Do not use more than 15 grams in one day.<br />If you use other calcipotriol containing medicines, the total<br />amount of calcipotriol medicines must not exceed 15 grams<br />per day and the area treated should not exceed 30 % of the<br />total body surface.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, Daivobet&reg; can cause side effects, although<br />not everybody gets them.<br />Approximately 1 in 12 people may experience side effects, but<br />most of these are reactions at the site where the gel has been<br />applied.<br /><u><strong>Serious side effects</strong></u><br />Tell your doctor/nurse immediately or as soon as possible if any<br />of the following happens. You may have to stop your treatment.<br />The following serious side effects have been reported for<br />Daivobet&reg;<br />Uncommon (affect less than 1 in 100 people)<br />&bull; Worsening of your psoriasis. If your psoriasis gets worse, tell<br />your doctor as soon as possible.<br />Some serious side effects are known to be caused by<br />betamethasone (a strong steroid), one of the ingredients in<br />Daivobet&reg;. You should tell your doctor as soon as possible if<br />any of the serious side effects occur. These side effects are<br />more likely to happen after long-term use, or use under<br />occlusion.<br />The side effects include the following:<br />&bull; Your adrenal glands may stop working properly. Signs are<br />tiredness, depression and anxiety.<br />&bull; Cataracts (signs are cloudy and foggy vision, difficulty<br />seeing at night and sensitivity to light) or an increase in<br />pressure inside your eye (signs are eye pain, red eye,<br />decreased or cloudy vision)<br />&bull; Infections (because your immune system, which fights<br />infections, may be suppressed or weakened)<br />&bull; Pustular psoriasis (a red area with yellowish pustules usually<br />on the hands or feet). If you notice this, stop taking Daivobet&reg;<br />and tell your doctor as soon as possible<br />&bull; Impact on the metabolic control of diabetes mellitus (if you<br />have diabetes you may experience fluctuations in the blood<br />gluclose levels).<br />Serious side effects known to be caused by calcipotriol<br />&bull; Allergic reactions with deep swelling of the face or other<br />parts of the body such as the hands or feet. Swelling of the<br />mouth/throat and trouble breathing may occur. If you have<br />an allergic reaction, stop taking Daivobet&reg;, tell your doctor<br />immediately or go to the casualty department at your nearest<br />hospital<br />&bull; Treatment with this gel may cause the level of calcium in<br />your blood or urine to increase (usually when too much gel<br />has been used). Signs of increased calcium in blood is bone<br />pain, constipation, poor appetite, nausea and vomiting. This<br />can be serious, and you should contact your doctor<br />immediately. However, when the treatment is stopped, the<br />levels return to normal.<br /><u><strong>Less serious side effects</strong></u><br />The following less serious side effects have been reported for<br />Daivobet&reg;<br />Common side effects (affect less than 1 in 10 people)<br />&bull; Itching.<br />Uncommon (affect less than 1 in 100 people)<br />&bull; Eye irritation<br />&bull; Burning sensation of the skin<br />&bull; Skin pain or irritation<br />&bull; Inflammation or swelling of the hair root (folliculitis)<br />&bull; Rash with inflammation of the skin (dermatitis)<br />&bull; Redness of the skin due to widening of the small blood<br />vessels (erythema)<br />&bull; Acne (pimples)<br />&bull; Dry skin<br />&bull; Rash<br />&bull; Pustular rash.<br />Less serious side effects caused by using betamethasone for<br />a long time, include the following, and you should tell your<br />doctor or nurse as soon as possible if you notice any of them<br />&bull; Thinning of the skin<br />&bull; Appearance of surface veins or stretch marks<br />&bull; Changes in hair growth<br />&bull; Red rash around the mouth (perioral dermatitis)<br />&bull; Skin rash with inflammation or swelling (allergic contact<br />dermatitis)<br />&bull; Small white spots (colloid milia)<br />&bull; Depigmentation (lightening of skin colour).<br />Less serious side effects known to be caused by calcipotriol<br />include the following<br />&bull; Sensitivity of the skin to light resulting in a rash<br />&bull; Eczema.<br />If you notice the above or any other changes in your health<br />while taking this medicine, tell your doctor.<br />If any of the side effects get serious, or if you notice any side<br />effects not listed in this leaflet, please tell your doctor or<br />pharmacist.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>&bull; Keep out of the reach and sight of children<br />&bull; Do not use Daivobet&reg; after the expiry date, which is stated<br />on the bottle after EXP. The expiry date refers to the last day<br />of that month<br />&bull; Do not refrigerate. Keep the bottle in the outer carton in order<br />to protect from light<br />&bull; Discard the bottle with any remaining gel 3 months after first<br />opening.<br />Medicines should not be disposed of via wastewater or<br />household waste. Ask your pharmacist how to dispose of<br />medicines no longer required.&nbsp;These measures will help to<br />protect the environment.</p><p>Storage conditions: Store below 30&deg; C.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>The active substances are:<br />Calcipotriol and betamethasone.<br />One gram of gel contains 50 micrograms of calcipotriol (as<br />monohydrate) and 0.5 mg of betamethasone (as dipropionate).<br />The other ingredients are:<br />&bull; paraffin, liquid<br />&bull; polyoxypropylene-15 stearyl ether<br />&bull; castor oil, hydrogenated<br />&bull; butylhydroxytoluene (E321)<br />&bull; all-rac-&alpha;-tocopherol.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Daivobet® is an almost clear, colourless to slightly off-white
gel filled in high-density polyethylene bottles with low-density
polyethylene nozzle and a high-density polyethylene screw cap.
The bottles are placed in cartons.
Pack sizes: 15, 30, 60 and 2 x 60 g.
Not all pack sizes may be marketed.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>The Marketing Authorisation holder is:<br />LEO Pharma A/S<br />Industriparken 55<br />DK-2750 Ballerup<br />Denmark<br />The manufacturer is:<br />LEO Pharma A/S<br />Industriparken 55<br />DK-2750 Ballerup<br />Denmark<br />For further information about this medicine, contact the local<br />representative of the Marketing Authorisation Holder</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                30. September 2010.
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL">يستعمل دايفوبيت<sup>&reg;</sup><strong> </strong>كعلاج موضعي لمرض صدفية فروة الرأس لدى البالغين وعلى جلد مناطق أخرى من الجسم لعلاج حالات خفيفة إلى معتدلة من الصداف اللويحي (الصدفية الشائعة) لدى البالغين.</p><p dir="RTL">ويتسبب مرض الصدفية من قبل خلايا الجلد التي يتم إنتاجها بسرعة كبيرة. وهذا يسبب احمرار وتقشر وسماكة الجلد.</p><p dir="RTL">يحتوي دايفوبيت<sup>&reg;</sup><strong> </strong>على كالسيبوتريول وبيتاميثاسون.</p><p dir="RTL">يساعد كالسيبوتريول على تحقيق معدل نمو خلايا الجلد وعودتها إلى حالتها العادية وبيتاميثاسون لتخفيف الالتهاب.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">لا تستخدم دايفوبيت<sup>&reg;</sup><strong> </strong>إذا:<strong> </strong></p><p dir="RTL">* كنت تشكو من حساسية (إفراط في الحساسية) لكالسيبوتريول، بيتاميثاسون أو أي من المكونات الأخرى في دايفوبيت<sup>&reg;</sup><strong>. </strong></p><p dir="RTL">* كان لديك مشاكل مع مستويات الكالسيوم في الجسم (اسأل طبيبك).</p><p dir="RTL">* كان لديك بعضاً من أنواع الصدفية: وهذه الأنواع هي الأحمرية، التقشري والبثري (اسأل طبيبك).</p><p dir="RTL">لأن دايفوبيت<sup>&reg;</sup><strong> </strong>يحتوي على ستيرويد قوي لذلك فإن استعماله محظور على الجلد المصاب بما يلي:</p><p dir="RTL">* الالتهابات التي تسببها الفيروسات (مثل القروح الباردة أو جدري الماء).</p><p dir="RTL">* الالتهابات التي يسببها نوع من الفطريات (مثل قدم الرياضي أو السعفة).</p><p dir="RTL">* الالتهابات التي تسببها البكتيريا.</p><p dir="RTL">* الالتهابات التي تسببها الطفيليات (الجرب على سبيل المثال).</p><p dir="RTL">* الدرن (السل) أو الزهري (السفلس).</p><p dir="RTL">* التهاب الجلد حول الفم (طفح جلدي أحمر حول الفم).</p><p dir="RTL">* ترقق الجلد، سهولة تلف الأوردة، علامات امتدادية.</p><p dir="RTL">* سماك (مثل الجلد الجاف مع قشور تشبه قشور السمك).</p><p dir="RTL">* حب الشباب (البثور).</p><p dir="RTL">* الوردية (تورّد شديد أو احمرار الجلد على الوجه).</p><p dir="RTL">* تقرحات أو تكسّر الجلد.</p><p dir="RTL">* حكة في الشرج (فتحة المؤخرة) أو الأعضاء (الأعضاء التناسلية).</p><p dir="RTL"><strong>مراعاة وتوخي الحذر مع دايفوبيت<sup>&reg;</sup> </strong></p><p dir="RTL">قبل استعمال هذا الدواء، أخبر طبيبك/ ممرضتك/ الصيدلاني إذا:</p><p dir="RTL">* كنت تستعمل أدوية أخرى تحتوي على ستيرويدات (منشطات) قشرية، بسبب احتمال حصول آثار جانبية.</p><p dir="RTL">* كنت قد استعملت هذا الدواء لفترة طويلة، وتفكر بإيقافه (فهناك خطورة في أن الصدفية ستتفاقم على نحو أسوأ أو &quot;تشتعل&quot; عندما يتم إيقاف الستيرويدات فجأة.</p><p dir="RTL">* مصاباً بسكري البول (داء السكري)، لأن مستوى السكر الدم/ الجلوكوز قد يتأثر من الستيرويد.</p><p dir="RTL">* أصيب جلدك بالتهابات، حينها يتطلب الأمر إيقاف العلاج.</p><p dir="RTL">* لديك نوع معين من الصدفية يسمى بالصداف النقطي.</p><p dir="RTL">* كنت مصاباً بداء خطير في الكبد أو الكلى.</p><p dir="RTL"><strong>الاحتياطات الخاصة: </strong></p><p dir="RTL">* تجنب استعمال على أكثر من 30% من جسمك أو استعمال أكثر من 15 جراماً يومياً.</p><p dir="RTL">* تجنب استعماله تحت غطاء الرأس والضمادات أو الضمادات المغلقة لأن هذا من شأنه أن يزيد من امتصاص الستيوريد.</p><p dir="RTL">* تجنب استعماله على مناطق واسعة من الجلد المتضرر أو طيات الجلد (في الفخذ، والآباط وتحت الثديين) لأن ذلك من شأنه أن يزيد من امتصاص الستيرويد.</p><p dir="RTL">* تجنب استعماله على وجهك أو الأعضاء (الأعضاء التناسلية) لأن هذه شديدة الحساسة للستيرويدات.</p><p dir="RTL">* تجنب الإفراط في حمامات الشمس، والاستعمال المفرط لحجرات التشمّس وغيرها من أشكال العلاج بالضوء.</p><p dir="RTL"><strong>الأطفال: </strong></p><p dir="RTL">لا ينصح باستعمال دايفوبيت<sup>&reg;</sup><strong> </strong>لدى الأطفال الذين تقل أعمارهم عن 18 سنة.</p><p dir="RTL"><strong>تناول أدوية أخرى: </strong></p><p dir="RTL">يرجى إبلاغ الطبيب أو الصيدلاني إذا كنت تتناول أو تناولت مؤخراً أي أدوية أخرى، بما في ذلك الأدوية التي تم الحصول عليها دون وصفة طبية.</p><p dir="RTL"><strong>الحمل والرضاعة الطبيعية: </strong></p><p dir="RTL">لا تستعملي دايفوبيت<sup>&reg;</sup><strong> </strong>إذا كنت حاملاً (أو يُحتمل أن تكوني حاملاً) أو في فترة الرضاعة الطبيعية، ما لم يكن هناك اتفاق مع طبيبك. إذا وافق الطبيب على أنه يمكنك إرضاع الثدي، يجب الحذر وعدم استعمال دايفوبيت<sup>&reg;</sup><strong> </strong>على منطقة الثدي.</p><p dir="RTL">اسأل طبيبك أو الصيدلاني للحصول على المشورة قبل استعمال أي عقار طبي.</p><p dir="RTL"><strong>القيادة واستعمال الآليات: </strong></p><p dir="RTL">ليس لهذا الدواء أي تأثير على قدرتك على قيادة السيارات أو استعمال الآلات.</p><p dir="RTL"><strong>معلومات هامة حول بعض مكونات دايفوبيت<sup>&reg;</sup>&nbsp; </strong></p><p dir="RTL">يحتوي دايفوبيت<sup>&reg;</sup><strong> </strong>على<strong> </strong>بيوتيليتيد هيدروزيتولوين (إي 321)، والذي قد يسبب ردود فعل جلدية موضعية (مثل التهاب الجلد التماسي)، أو تهيج العيون والأغشية المخاطية.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">استعمل دايفوبيت<sup>&reg;</sup><strong> </strong>دائماً حسب تعليمات الطبيب. يجب أن تتحقق من الطبيب أو الصيدلاني إن لم تكن متأكداً.</p><p dir="RTL">كيفية وضع دايفوبيت<sup>&reg;</sup>: استعمال جلدي.</p><p dir="RTL"><strong>تعليمات للاستعمال الصحيح: </strong></p><p dir="RTL">* استعمله فقط على المنطقة المصابة بالصدفية ولا تستعمله على الجلد غير المصاب بالصدفية.</p><p dir="RTL">* رج القنينة قبل الاستعمال وإزالة الغطاء.</p><p dir="RTL">* اضغط الهلام (الجل) على إصبع نظيفة أو مباشرة على المنطقة المصابة بالصدفية.</p><p dir="RTL">* ضع دايفوبيت<sup>&reg;</sup><strong> </strong>على المنطقة المصابة بأطراف أصابعك، وفرك بلطف حتى تغطي المنطقة المصابة بالصدفية بطبقة رقيقة من الهلام.</p><p dir="RTL">* لا تضمّد، أو تغطي بإحكام أو تلّف منطقة الجلد المُعالجة.</p><p dir="RTL">* اغسل يديك بشكل جيد بعد استعمال دايفوبيت<sup>&reg;</sup>. هذا سوف يجنبك نشر الهلام، بطريق الخطأ، إلى أجزاء أخرى من الجسم (وخاصة الوجه والفم والعينين).</p><p dir="RTL">* لا تقلق إذا تسرّب بعض الهلام بطريق الخطأ إلى الجلد الطبيعي بالقرب من منطقة الصدفية، بل قم بإزالته إذا ما انتشر في مناطق بعيدة عن المنطقة المصابة.</p><p dir="RTL">* من أجل تحقيق تأثير أفضل، من المستحسن، عدم الاستحمام أو الاستحمام مباشرة بعد استعمال هلام دايفوبيت<sup>&reg;</sup><strong>. </strong></p><p dir="RTL">* تجنب بعد استعمال الهلام، التماس مع المنسوجات التي تتلطخ بسهولة بالشحوم (مثل الحرير).</p><p dir="RTL"><strong>إذا كنت مصاباً بصدفية فروة الرأس</strong></p><p dir="RTL">* مشط شعرك لإزالة أي قشور وبقايا قبل وضع دايفوبيت<sup>&reg;</sup><strong>. </strong></p><p dir="RTL">أمل رأسك للتأكد من عدم تسرب دايفوبيت<sup>&reg;</sup> على وجهك. تقسيم منطقة الشعر قد تساعد قبل استعمال دايفوبيت<sup>&reg;</sup>. ضع دايفوبيت<sup>&reg;</sup><strong> </strong>على المنطقة المصابة بأطراف أصابعك، وفرك بلطف.</p><p dir="RTL">* عادة ما تكون الكمية التي تتراوح بين 1 و 4 جرامات يومياً كافية لعلاج فروة الرأس (4 جرامات تعادل ملعقة صغيرة).</p><p dir="RTL">* لا ضرورة لغسل شعرك قبل استعمال دايفوبيت<sup>&reg;</sup>.</p><p dir="RTL">* من المستحسن، لأجل تحقيق تأثير أفضل، أن لا يغسل الشعر مباشرة بعد استعمال دايفوبيت<sup>&reg;</sup><strong>. </strong>اترك دايفوبيت<sup>&reg;</sup><strong> </strong>على فروة الرأس أثناء الليل أو أثناء النهار.</p><p dir="RTL"><strong>مدة العلاج: </strong></p><p dir="RTL">* استعمل الهلام مرة واحدة في اليوم. قد يكون استعماله في المساء ملائماً أكثر.</p><p dir="RTL">* فترة العلاج الأولية الاعتيادية تستغرق 4 أسابيع فيما يتعلق بعلاج فروة الرأس و8 أسابيع للمناطق الأخرى.</p><p dir="RTL">* قد يتخذ طبيبك قراراً بشأن فترة علاج مختلفة.</p><p dir="RTL">* قد يقرر الطبيب تكرار العلاج.</p><p dir="RTL">* لا تستعمل أكثر من 15 جراماً في اليوم الواحد.</p><p dir="RTL">إذا كنت تستعمل أدوية أخرى تحتوي على كالسيبوتريول، فيجب أن لا تتجاوز كمية الكالسيبوتريول 15 جراماً في اليوم والمنطقة المعالجة يجب أن لا تتجاوز 30% من مجموع سطح الجسم.</p><p dir="RTL"><strong>ماذا ينبغي أن أتوقع عند استعمال دايفوبيت<sup>&reg;</sup>؟ </strong></p><p dir="RTL">يلاحظ معظم المرضى نتائج واضحة بعد مضي أسبوعين، حتى لو لم يتم التخلص من الصدفية في تلك المرحلة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">مثل جميع الأدوية، فإن دايفوبيت<sup>&reg;</sup> يمكن أن يتسبب في آثار جانبية، بالرغم من أن هذا لا يشمل الجميع.</p><p dir="RTL">قرابة شخص واحد من اثني عشر شخصاً قد يعاني من الآثار الجانبية، ولكن معظمها ردود فعل في الموضع الذي استعمل عليه الهلام.</p><p dir="RTL"><u>الآثار الجانبية الخطيرة</u></p><p dir="RTL">أبلغ الطبيب / الممرضة فوراً أو في أقرب وقت ممكن في حال حدوث ما يلي. قد تضطر إلى التوقف عن العلاج. الآثار الجانبية الخطيرة التالية حدثت جراء استعمال دايفوبيت<sup>&reg;</sup></p><p dir="RTL">من غير المألوف (تؤثر على أقل من 1 لكل 100 شخص)</p><p dir="RTL">* تفاقم مرض الصدفية. في هذه الحالة أخبر طبيبك بأقرب وقت ممكن.</p><p dir="RTL">ومن المعروف أن بعض الآثار الجانبية الخطيرة تكون بسبب بيتاميثاسون (منشط قوي)، أحد المكونات في دايفوبيت<sup>&reg;</sup>. يجب أن تخبر طبيبك في أقرب وقت ممكن في حال حدوث أي من الآثار الجانبية الخطيرة. من المرجح أن تحدث هذه الآثار الجانبية بعد استعمال طويل الأجل، أو استعماله تحت ضمادات مغلفة.</p><p dir="RTL">الآثار الجانبية تتضمن ما يلي:</p><p dir="RTL">* توقف وظيفة الغدد الكظرية عن العمل بشكل صحيح. والأعراض تشمل التعب والاكتئاب والقلق.</p><p dir="RTL">* إعتام عدسة العين (الأعراض تشمل الرؤية الغائمة والضبابية، وصعوبة الرؤية في الليل والحساسية للضوء) أو زيادة في الضغط داخل العين (تشمل الأعراض ألم في العين، احمرار العين، انخفاض الرؤية أو الرؤية الضبابية).</p><p dir="RTL">* التهابات (بسبب النظام المناعي الذي يكافح الإصابات، مما قد يعيق أو يضعف وظيفته).</p><p dir="RTL">* الصداف البثري (منطقة حمراء مع بثور صفراء تظهر عادة على اليدين أو القدمين). توقف عن استعمال دايفوبيت<sup>&reg;</sup> إذا لاحظت هذا، وأخبر طبيبك في أقرب وقت ممكن.</p><p dir="RTL">* التأثير على السيطرة الأيضية لداء السكري (قد تواجهك تقلبات في مستويات جلوكوز الدم إذا كنت مصاباً بداء السكري).</p><p dir="RTL">آثار جانبية خطيرة معروفة سببها الكالسيبوتريول</p><p dir="RTL">* حساسية مع تورم عميق في الوجه العميق أو أجزاء أخرى من الجسم مثل اليدين أو القدمين. قد يحدث تورم في الفم / الحلق وصعوبة في التنفس. توقف عن تناول دايفوبيت<sup>&reg;</sup> إذا تعرضت لردود فعل الحساسية وأخبر طبيبك على الفور أو راجع قسم الإصابات في أقرب مستشفى.</p><p dir="RTL">* قد تزيد المعالجة بهذا الهلام من مستوى الكالسيوم في الدم أو البول (عادة عند استعمال الكثير من الهلام). وأعراض زيادة الكالسيوم في الدم تكون آلام العظام، الإمساك، ضعف الشهية والغثين والقيء.</p><p dir="RTL">هذه الأعراض يمكن أن تكون خطيرة، ولذلك يجب عليك الاتصال بطبيبك على الفور. ومع ذلك، عند توقف العلاج، تعود المستويات إلى طبيعتها.</p><p dir="RTL"><u>آثار جانبية أقل خطورة</u></p><p dir="RTL">تم الإبلاغ عن الآثار الجانبية التالية الأقل خطورة لدايفوبيت<sup>&reg;</sup></p><p dir="RTL">التأثيرات الجانبية الشائعة (تؤثر على أقل من 1 لكل 10 أشخاص)</p><p dir="RTL">* الحكة</p><p dir="RTL">من غير المألوف (تؤثر على أقل من 1 لكل 100 شخص).</p><p dir="RTL">* تهيج العين.</p><p dir="RTL">* الإحساس بالحرقان في الجلد.</p><p dir="RTL">* ألم أو تهيج الجلد.</p><p dir="RTL">* التهاب أو تورم في جذور الشعر (التهاب الجريبات).</p><p dir="RTL">* الطفح الجلدي مع التهاب الجيد (أكزيما).</p><p dir="RTL">* احمرار في الجلد بسبب اتساع الأوعية الدموية الصغيرة (حمامي).</p><p dir="RTL">* حب الشباب (البثور).</p><p dir="RTL">* البشرة الجافة.</p><p dir="RTL">* الطفح.</p><p dir="RTL">* الطفح البثري.</p><p dir="RTL">آثار جانبية أقل خطورة بسبب استعمال بيثاميثاسون لفترة طويلة تشمل ما يلي، وينبغي عليك أن تُعلم الطبيب أو الممرضة في أقرب وقت ممكن إذا لاحظت أي من هذه الأعراض.</p><p dir="RTL">* ترقق الجلد.</p><p dir="RTL">* ظهور الأوردة السطحية أو علامات التمدد.</p><p dir="RTL">* تغيرات في نمو الشعر.</p><p dir="RTL">* طفح جلدي أحمر حول الفم (التهاب الجلد حول الفم).</p><p dir="RTL">* طفح جلدي مع التهاب أو تورم (حساسية التهاب الجلد بالتماس).</p><p dir="RTL">* البقع البيضاء الصغيرة (ميليا غرواني).</p><p dir="RTL">* تصبغ (برق لون البشر).</p><p dir="RTL">آثار جانبية خطيرة معروفة أقل سببها كالسيبوتريول تشمل ما يلي:</p><p dir="RTL">* حساسية الجلد للضوء مما يؤدي إلى الطفح.</p><p dir="RTL">* الأكزيما.</p><p dir="RTL">إذا لاحظت أي من الأعراض أعلاه، أو أية تغييرات أخرى في صحتك حين أخذ هذا الدواء، أخبر طبيبك.</p><p dir="RTL">إذا أصبح أي من الآثار الجانبية خطراً، أو إذا لاحظت أي آثار غير مدرجة في هذه النشرة، يرجى إخبار الطبيب أو الصيدلاني.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">* يُحفظ بعيداً عن متناول ورؤية الأطفال.</p><p dir="RTL">* لا تستعمل دايفوبيت<sup>&reg;</sup> بعد تاريخ انتهاء الصلاحية، والذي ورد على الزجاجة بعد EXP. تاريخ الانتهاء يشير إلى اليوم الأخير من ذاك الشهر.</p><p dir="RTL">* لا تُبّرده. أبق الزجاجة في الكرتونة الخارجية لحمايتها من الضوء.</p><p dir="RTL">* تخلّص من الزجاجة والهلام المتبقي بعد 3 أشهر من فتحها.</p><p dir="RTL">لا ينبغي التخلص من الأدوية عن طريق مياه الصرف الصحي أو عن طريق النفايات المنزلية. اسأل الصيدلاني عن كيفية التخلص من الأدوية التي لا حاجة إليها. من شأن هذه التدابير أن تساعد على حماية البيئة.</p><p dir="RTL"><strong>شروط التخزين: </strong>يُخزّن في أقل من 30 درجة مئوية</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">المواد الفعالة هي:</p><p dir="RTL">كالسيبوتريول وبيتاميثاسون.</p><p dir="RTL">جرام واحد من الهلام يحتوي على 50 ميكروجرام من كالسيبوتريول (كمونوهيدرات) و 0.5 مليجرام من بيتاميثاسون (كديبروبيونات).</p><p dir="RTL">المكونات الأخرى هي:</p><p dir="RTL">* البارافين، سائل.</p><p dir="RTL">* بولوزيبروبيلين &ndash; 15 ستيريل أثير.</p><p dir="RTL">* زيت الخروع، مهدرج.</p><p dir="RTL">* بيوتيليتيد هيدروزيتولوين (إي 321).</p><p>* جميع - راك - &alpha; - توكوفيرول</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL" style="text-align:right">دايفوبيت<sup>&reg;</sup> هو هلام صافي تقريباً، عديم اللون يميل إلى الأبيض قليلاً مُعبّأ في زجاجات البولي إثيلين عالي الكثافة مع بزباز من البولي إثيلين منخفض الكثافة وسدادة لولبية من البولي إثيلين عالي الكثافة.</p><p dir="RTL" style="text-align:right">يتم وضع هذه العبوات في علب كرتونية.</p><p dir="RTL" style="text-align:right">أحجام الكرتونة: 15، 30، 60 و 2 &times; 60 جم</p><p dir="RTL" style="text-align:right">قد لا يتم تسويق جميع الأحجام.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>صاحب رخصة التسويق والشركة المصنعة </strong></p><p dir="RTL">صاحب رخصة التسويق هو:</p><p dir="RTL">LEO Pharma A/S</p><p dir="RTL">Industriparken 55</p><p dir="RTL">DK-2750 Ballerup</p><p dir="RTL">Denmark</p><p dir="RTL">الشركة المصنعة:</p><p dir="RTL">LEO Pharma A/S</p><p dir="RTL">Industriparken 55</p><p dir="RTL">DK-2750 Ballerup</p><p dir="RTL">Denmark</p><p dir="RTL">للمزيد من المعلومات حول هذا الدواء يرجى الاتصال بالممثل المحلي لـ</p><p dir="RTL">&ldquo;Marketing Authorisation Holder Local Representative&rdquo;</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            30 سبتمبر 2010. 
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Daivobet 50 micrograms/0.5 mg/g gel 
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                One gram of gel contains 50 micrograms of calcipotriol (as monohydrate) and 0.5 mg of betamethasone (as dipropionate).

Excipient: 160 micrograms butylated hydroxytoluene/g gel 
For a full list of excipients, see section 6.1.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Gel.
An almost clear, colourless to slightly off-white gel.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Topical treatment of scalp psoriasis in adults. Topical treatment of mild to moderate &quot; non-scalp&quot; plaque psoriasis vulgaris in adults.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Posology</u></p><p>Daivobet gel should be applied to affected areas once daily. The recommended treatment period is 4 weeks for scalp areas and 8 weeks for &quot; non-scalp&quot; areas. If it is necessary to continue or restart treatment after this period, treatment should be continued after medical review and under regular medica l supervision.</p><p>&nbsp;</p><p>When using calcipotriol containing medicinal products, the maximum&nbsp; daily dose should not exceed 15 g. The body surface area treated with calcipotriol containing medicinal products should not exceed 30 % (see section 4.4).</p><p>&nbsp;</p><p><em>When&nbsp;</em><em>used on the sc</em><em>a</em><em>lp</em></p><p>All the affected scalp areas may be treated with Daivobet gel. Usually an amount between 1 g and 4 g per day is sufficient for treatment of the scalp (4 g corresponds to one teaspoon).</p><p>&nbsp;</p><p><u>Special populations</u></p><p><em>Ren</em><em>a</em><em>l </em><em>a</em><em>nd h</em><em>e</em><em>p</em><em>a</em><em>tic i</em><em>m</em><em>pair</em><em>m</em><em>en</em><em>t</em></p><p>The safety and efficacy of Daivobet gel in patients with severe renal insufficiency or severe hepatic disorders have not been evaluated.</p><p>&nbsp;</p><p><u>Paediatric population</u></p><p>The safety and efficacy of Daivobet gel in children below 18 years have not been estab lished. No data are available.</p><p>&nbsp;</p><p><u>Method of administration</u></p><p>The bottle should be shaken before use and Daivobet gel applied to the affected area. Daivobet gel should not be applied directly to the face or eyes. The hands should be washed after use. In order to achieve optimal effect, it is not recommended to take a shower or bath, or to wash the hair in case of scalp application, immediately after application of Daivobet gel. Daivobet gel should remain on the skin during the night or during the day.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Hypersensitivity to the active substances or to any of the excipients.



Daivobet gel is contraindicated in erythrodermic, exfoliative and pustular psoriasis.



Due to the content of calcipotriol, Daivobet gel is contraindicated in patients with known disorders of calcium metabolism .

Due to the content of corticosteroid, Daivobet gel is contraindicated in the following conditions: Viral (e.g. herpes or varicella) lesions of the skin, fungal or bacterial skin infections, parasitic infections, skin manifestations in relation to tuberculosis or syphilis, perioral dermatitis, atrophic skin, striae atrophicae, fragility of skin veins, ichthyosis , acne vulgaris , acne rosacea, rosacea, ulcers, wounds, perianal and genital pruritus.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Effects on endocrine system</u></p><p>Daivobet gel contains a potent group III steroid and concurrent treatment with other steroids must be avoided. Adverse reactions found in connection with systemic corticosteroid treatment, such as adrenocortical suppression or impact on the metabolic control of diabetes mellitus, may occur also during topical corticosteroid treatment due to systemic absorption. Application under occlusive dressings should be avoided since it increases the systemic absorption of corticosteroids. Application on large areas of damaged skin or on mucous membranes or in skin folds should be avoided since it increases the systemic absorption of corticosteroids (see section 4.8).</p><p>&nbsp;</p><p>In a study in patients with both extensive scalp and extensive body psoriasis using a combination of high doses of Daivobet gel (scalp application) and high doses of Daivobet ointment (body application), 5 of 32 patients showed a borderline decrease in cortisol response to adrenocorticotropic hormone (ACTH) challenge after 4 weeks of treatment (see section 5.1).</p><p>&nbsp;</p><p><u>Effects on calcium metabolism</u></p><p>Due to the content of calcipotriol, hypercalcaemia may occur if the maximum daily dose (15 g) is exceeded. Serum calcium is, however, quickly normalised when treatment is discontinued. The risk of hypercalcaemia is minimal when the recommendations relevant to calcipotriol are followed.</p><p>Treatment of more than 30 % of the body surface should be avoided (see section 4.2).</p><p>&nbsp;</p><p><u>Local adverse reactions</u></p><p>Skin of the face and genitals are very sensitive to corticostesroids. The medicinal product should not be used in these areas. Uncommon local adverse reactions (such as eye irritation or irritation of facial skin) were observed, when the medicinal product was accidentally administered in the area of face, or accidentally to the eyes or conjunctives (see sections 4.8 and 5.1). The patient must be instructed in correct use of the medicinal product to avoid application and accidental transfer to the face, mouth and eyes. Hands must be washed after each application to avoid accidental transfer to these areas.</p><p>&nbsp;</p><p><u>Concomitant skin infections</u></p><p>When lesions become secondarily infected, they should be treated with antirmicrobiological therapy. However, if infection worsens , treatment with corticosteroids should be stopped.</p><p>&nbsp;</p><p><u>Discontinuation of treatment</u></p><p>&nbsp;</p><p>When treating psoriasis with topical corticosteroids, there may be a risk of generalised pustular psoriasis or of rebound effects when discontinuing treatment. Medical supervision should therefore continue in the post-treatment period.</p><p>&nbsp;</p><p><u>Long-term use</u></p><p>With long-term use there is an increased risk of local and systemic corticosteroid adverse reactions. The treatment should be discontinued in case of adverse reactions related to long-term use of corticosteroid (see section 4.8).</p><p>&nbsp;</p><p><u>Unevaluated uses</u></p><p>There is no experience for the use of Daivobet gel in guttate psoriasis .</p><p>&nbsp;</p><p><u>Concurrent treatment and UV exposure</u></p><p>Daivobet ointment for body psoriasis lesions has been used in combination with Daivobet gel for scalp psoriasis lesions, but there&nbsp; is no experience of combination of Daivobet&nbsp; with other topical anti&shy; psoriatic products at the same treatment area, other anti-psoriatic medicinal products administered systemically or with phototherapy.</p><p>&nbsp;</p><p>During Daivobet gel treatment, physicians are recommended to advise patients to limit or avoid excessive exposure to either natural or artificial sunlight. Topical calcipotriol should be used with UVR only if the physician and patient consider that the potential benefits outweigh the potential risks (see section 5.3).</p><p>&nbsp;</p><p><u>Adverse reactions to excipients</u></p><p>Daivobet gel contains butylated hydroxytoluene (E321), which may cause local skin reactions (e.g. contact dermatitis), or irritation to the eyes and mucous membranes.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>&nbsp;</p><p>No interaction studies have been performed.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Pregnancy</u></p><p>There are no adequate data from the use of Daivobet gel in pregnant women . Studies in animals with glucocorticoids have shown reproductive toxicity (see section 5.3), but a number of epidemiological studies have not revealed congenital anomalies among infants born to women treated with corticosteroids during pregnancy. The potential risk for humans is uncertain. Therefore, during pregnancy, Daivobet gel should only be used when the potential benefit justifies the potential risk.</p><p>&nbsp;</p><p><u>Breastfeeding</u></p><p>Betamethasone passes into breast milk, but risk of an adverse effect on the infant seems unlikely with therapeutic doses. There are no data on the excretion of calcipotriol in breast milk. Caution should be exercised when prescribing Daivobet gel to women who breast-feed. The patient should be instructed not to use Daivobet on the breast when breast-feeding.</p><p>&nbsp;</p><p><u>Fertility</u></p><p>Studies in rats with oral doses of calcipotriol or betamethasone dipropionate demonstrated no impairment of male and female fertility.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Daivobet gel has no influence on the ability to drive and use machines.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The clinical trial programme for Daivobet gel has so far included more than 4,700 patients of whom more than 2,100 were treated with Daivobet gel. Approximately 8 % of patients treated with Daivobet gel experienced a non-serious adverse reaction.</p><p>These reactions are usually mild and cover mainly various skin reactions with pruritus being the most common.</p><p>&nbsp;</p><p>Based on data from clinical trials and post market use the following adverse reactions are listed for Daivobet gel.</p><p>The adverse reactions are listed by MedDRA System Organ Class, and the individual adverse reactions are listed starting with the most frequently reported. Within each frequency grouping, the adverse reactions are listed in order of decreasing seriousness.</p><p>The following terminologies have been used in order to classify the frequencies of adverse reactions:</p><p>&nbsp;</p><p>Very common&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 2:1/10</p><p>Common&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 2:1/100 to &lt;1/10</p><p>Uncommon&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 2:1/1,000 to &lt;1/100</p><p>Rare&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 2:1/10,000 to &lt;1/1,000</p><p>Very rare&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &lt;1/10,000</p><p>Not known (cannot be estimated from the available data)</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td colspan="2" style="vertical-align:top"><p><strong>Eve disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Eye irritation</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Skin and subcutaneous tissue disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Pruritus</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Exacerbation of psoriasis Burning sensation of skin Skin pain or irritation Folliculitis</p><p>Dermatitis Erythema Acne</p><p>Dry skin Rash Pustular rash</p></td></tr></tbody></table><p>&nbsp;</p><p>The following adverse reactions are considered to be related to the pharmacological classes of calcipotriol and betamethasone, respectively:</p><p>&nbsp;</p><p><u>Calcipotriol</u></p><p>Adverse reactions include application site reactions, pruritus, skin irritation, burning and stinging sensation, dry skin, erythema, rash, dermatitis, eczema, psoriasis aggravated, photosensitivity and hypersensitivity reactions including very rare cases of angioedema and facial oedema.</p><p>Systemic effects after topical use may appear very rarely causing hypercalcaemia or hypercalciuria (see section 4.4).</p><p>&nbsp;</p><p><u>Betamethasone (as dipropionate)</u></p><p>Local reactions can occur after topical use, especially during prolonged application, including skin atrophy, telangiectasia, striae, folliculitis, hypertrichosis, perioral dermatitis, allergic contact dermatitis, depigmentation and colloid milia. When treating psoriasis there may be a risk of generalised pustular psoriasis.</p><p>Systemic reactions due to topical use of corticosteroids are rare in adults, however they can be severe. Adrenocortical suppression, cataract, infections, impact on the metabolic control of diabetes mellitus and increase of intra-ocular pressure can occur, especially after long term treatment. Systemic reactions occur more frequently when applied under occlusion {plastic, skin folds), when applied on large areas and during long term treatment (see section 4.4).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Use above the recommended dose may cause elevated serum calcium which should rapidly subside when treatment is discontinued.</p><p>Excessive prolonged use of topical corticosteroids may suppress the pituitary-adrenal functions, resulting in secondary adrenal insufficiency which is usually reversible. In such cases, symptomatic treatment is indicated.</p><p>In case of chronic toxicity, the corticosteroid treatment must be discontinued gradually.</p><p>&nbsp;</p><p>It has been reported that due to misuse one patient with extensive erythrodermic psoriasis treated with 240 g of Daivobet ointment weekly (corresponding to a daily dose of approximately 34 g) for 5 months (maximum recommended dose 15 g daily) developed Cushing&#39;s syndrome and pustular psoriasis after abruptly stopping treatment</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: Antipsoriatics. Other antipsoriatics for topical use, Calcipotriol, combinations. ATC Code: D05AX52</p><p>&nbsp;</p><p>Calcipotriol is a vitamin D analogue. In vitro data suggest that calcipotriol induces differentiation and suppresses proliferation of keratinocytes. This is the proposed basis for its effect in psoriasis.</p><p>&nbsp;</p><p>Like other topical corticosteroids, betamethasone dipropionate has anti-inflammatory, antipruritic, vasoconstrictive and immunosuppresive properties, however, without curing the underlying condition. Through occlusion the effect can be enhanced due to increased penetration of the stratum comeum.</p><p>The incidence of adverse events will increase because of this. In general, the mechanism of the anti&shy; inflammatory activity of the topical steroids is uncle ar.</p><p>&nbsp;</p><p>Adrenal response to ACTH was determined by measuring serum cortisol levels in patients with both extensive scalp and body psoriasis, using up to 106 g per week combined Daivobet gel and Daivobet ointment. A borderline decrease in cortisol response at 30 minutes post ACTH challenge was seen in 5 of32 patients (15.6 %) after 4 weeks of treatment and in 2 of 11 patients (18.2 %) who continued treatment until 8 weeks. In all cases, the serum cortisol levels were normal at 60 minutes post ACTH challenge. There was no evidence of change of calcium metabolism observed in these patients. With regard to HPA suppression, therefore, this study shows some evidence that very high doses of Daivobet gel and ointment may have a weak effect on the HPA axis.</p><p>&nbsp;</p><p>The efficacy of once daily use of Daivobet gel was investigated in two randomised, double-blind, 8- week clinical studies including a total of more than 2,900 patients with scalp psoriasis of at least mild severity according to the Investigator&#39;s Global Assessment of disease severity (IGA). Comparators were betamethasone dipropionate in the gel vehicle, calcipotriol in the gel vehicle and (in one of the studies) the gel vehicle alone, all used once daily. Results for the primary response criterion (absent or very mild disease according to the IGA at week 8) showed that Daivobet gel was statistically significantly more effective than the comparators. Results for speed of onset based on similar data at week 2 also showed Daivobet gel to be statistically significantly more effective than the comparators.</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>% of patients with</p><p>absent or very mild disease</p></td><td style="vertical-align:top"><p>Daivobet gel (n= l,108)</p></td><td style="vertical-align:top"><p>Betamethasone</p><p>dipropionate (n= l,118)</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>Calcipotriol (n=558)</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>Gel vehicle (n=136)</p></td></tr><tr><td style="vertical-align:top"><p>week2</p></td><td style="vertical-align:top"><p>53.2 %</p></td><td style="vertical-align:top"><p>42.8 %1</p></td><td style="vertical-align:top"><p>17.2 %1</p></td><td style="vertical-align:top"><p>11.8 %1</p></td></tr><tr><td style="vertical-align:top"><p>week 8</p></td><td style="vertical-align:top"><p>69.8 %</p></td><td style="vertical-align:top"><p>62.5 %1</p></td><td style="vertical-align:top"><p>40.1 %1</p></td><td style="vertical-align:top"><p>2 2.8 %1</p></td></tr></tbody></table><p>1 Statistically significantly less effective than Daivobet gel {P&lt;0.001)</p><p>&nbsp;</p><p><!--[if gte vml 1]><v:shapetype id="_x0000_t202" coordsize="21600,21600"
 o:spt="202" path="m,l,21600r21600,l21600,xe">
 <v:stroke joinstyle="miter"/>
 <v:path gradientshapeok="t" o:connecttype="rect"/>
</v:shapetype><v:shape id="_x0000_s1026" type="#_x0000_t202" style='position:absolute;
 left:0;text-align:left;margin-left:87.4pt;margin-top:105.35pt;width:399.45pt;
 height:74.3pt;text-indent:0;z-index:251658240;
 mso-position-horizontal-relative:page' filled="f" stroked="f">
 <v:textbox inset="0,0,0,0"/>
 <w:wrap anchorx="page"/>
</v:shape><![endif]--></p><table cellpadding="0" cellspacing="0"><tbody><tr><td><table cellpadding="0" cellspacing="0" style="width:100%"><tbody><tr><td><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>% of patients with controlled disease</p></td><td style="vertical-align:top"><p>Daivo bet gel (n=l26)</p></td><td style="vertical-align:top"><p>Betamethasone</p><p>dipropionate (n=68)</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>Calcipotriol (n=67)</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>Gel vehicle (n=35)</p></td></tr><tr><td style="vertical-align:top"><p>week 4</p></td><td style="vertical-align:top"><p>20.6%</p></td><td style="vertical-align:top"><p>10.3 %1</p></td><td style="vertical-align:top"><p>4 .5 %1</p></td><td style="vertical-align:top"><p>2 .9 % <sup>1</sup></p></td></tr><tr><td style="vertical-align:top"><p>week 8</p></td><td style="vertical-align:top"><p>31.7 %</p></td><td style="vertical-align:top"><p>19.1 %1</p></td><td style="vertical-align:top"><p>13.4 %1</p></td><td style="vertical-align:top"><p>0 . 0 %1</p></td></tr></tbody></table><p>&nbsp;</p></td></tr></tbody></table></td></tr></tbody></table><p>The efficacy of once daily use of Daivobet gel on non-scalp regions of the body was investigated in a randomised, double - blind, 8-week clinical study including 296 patients with psoriasis vulgaris of mild or moderate severity according to the IGA. Comparators were betamethasone dipropionate in the gel vehicle, calcipotriol in the gel vehicle and the gel vehicle alone, all used once daily. Primary response criteria were controlled disease accbrding to the IGA at week 4 and week 8. Controlled disease was defined as &#39; clear&#39; or &#39;minimal disease&#39; for patients with moderate disease at baseline or &#39; clear&#39; for patients with mild disease at baseline. The percentage change in Psoriasis Severity and Area index (PASI) from baseline to week 4 and week 8 were secondary response criteria.</p><p>&nbsp;</p><p>1 Statistically significantly less effective than Daivobet gel {P&lt;0.05)</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>Mean percentage</p><p>reduct ion in PASI (SD)</p></td><td style="vertical-align:top"><p>Daivobet gel (n= l 26)</p></td><td style="vertical-align:top"><p>Betamethasone</p><p>dipropionate (n=68)</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>Calcipotriol (n=67)</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>Gel vehicle</p><p><em>(n=35)</em></p></td></tr><tr><td style="vertical-align:top"><p>week4</p></td><td style="vertical-align:top"><p>50.2 (32.7)</p></td><td style="vertical-align:top"><p>40.8 (33.3)1</p></td><td style="vertical-align:top"><p>3 2.1 (23.6i</p></td><td style="vertical-align:top"><p>17.0 (31.8)1</p></td></tr><tr><td style="vertical-align:top"><p>week 8</p></td><td style="vertical-align:top"><p>58.8 (32.4)</p></td><td style="vertical-align:top"><p>51.8 (35.0)</p></td><td style="vertical-align:top"><p>40.8 (31.9)1</p></td><td style="vertical-align:top"><p>11.1 (29.5)1</p></td></tr></tbody></table><p>1 Statis tically significantly less effective than Daivobet gel (P&lt;0.05)</p><p>&nbsp;</p><p>Another randomised, investigator-blinded clinical study including 312 patients with scalp psoriasis of at least moderate severity according to the IGA investigated use of Daivobet gel once daily compared with Daivonex Scalp solution twice daily for up to 8 weeks. Results for the primary response criterion (absent or very mild disease according to the IGA at week 8) showed that Daivobet gel was statistically significantly more effective than Daivonex Scalp solution.</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>% of patients with</p><p>absent or very mild disease</p></td><td style="vertical-align:top"><p>Daivobet gel (n=207)</p></td><td style="vertical-align:top"><p>Daivonex Sca lp</p><p>solution (n=105)</p></td></tr><tr><td style="vertical-align:top"><p>week 8</p></td><td style="vertical-align:top"><p>68.6%</p></td><td style="vertical-align:top"><p>31.4 %1</p></td></tr></tbody></table><p>1 Statistically significantly less effective than Daivobet gel (P&lt;0.001)</p><p>&nbsp;</p><p>A randomised, double-blind long-term clinica l study including 873 patients with scalp psoriasis of at least moderate severity (according to the IGA) investigated the use of Daivobet gel compared with calcipotriol in the gel vehicle. Both treatments were applied once daily, intermittently as required, for up to 52 weeks. Adverse events possibly related to long-term use of corticosteroids on the scalp, were identified by an independent, blinded panel of dermatologists. There was no difference in the percentages of patients experiencing such adverse events between the treatment groups (2.6 % in the Daivobet gel group and 3.0 % in the calcipotriol group; P=0.73). No cases of skin atrophy were reported.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The systemic exposure to calcipotriol and betamethasone dipropionate from topically applied Daivobet gel is comparable to Daivobet ointment in rats and minipigs. Clinical studies with radiolabelled ointment indicate that the systemic absorption of calcipotriol and betamethasone from Daivobet ointment formulation is less than l % of the dose (2.5 g) when applied to normal skin&nbsp;<span style="text-align:unset">(625 cm2</span>)&nbsp;for 12 hours. Application to psoriasis plaques and under occlusive dressings may increase the absorption of topical corticosteroids. Absorption through damaged skin is approx. 24 %.</p><p>Following systemic exposure, both active ingredients - calcipotriol and betamethasone dipropionate - are rapidly and extensively metabolised. Protein binding is approx. 64 %. Plasma elimination half-life after intravenous application is 5-6 hours. Due to the formation of a depot in the skin elimination after dermal application is in order of days. Betamethasone is metabolised especially in the liver, but also in the kidneys to glucuronide and sulphate esters. The main route of excretion of calcipotriol is via faeces (rats and minipigs) and for betamethasone dipropionate it is via urine (rats and mice). In rats, tissue distribution studies with radiolabelled calcipotriol and betamethasone dipropionate, respectively, showed that the kidney and liver had the highest level of radioactivity.</p><p>Calcipotriol and betamethasone dipropionate were below the lower limit of quantification in all blood samples of 34 patients treated for 4 or 8 weeks with both Daivobet gel and Daivobet ointment for extensive psoriasis involving the body and scalp. One metabolite of calcipotriol and one metabolite of betamethasone dipropionate were quantifiable in some of the patients</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Studies of corticosteroids in animals have shown reproductive toxicity (cleft palate, skeletal malformations). In reproduction toxicity studies with long-term oral administration of corticosteroids to rats, prolonged gestation and prolonged and difficult labour were detected. Moreover, reduction in offspring survival, body weight and body weight gain was observed. There was no impairment of fertility. The relevance for humans is unknown.</p><p>&nbsp;</p><p>A dermal carcinogenicity study with calcipotriol in mice revealed no special hazard to humans.</p><p>&nbsp;</p><p>Photo(co)carcinogenicity studies in mice suggest that calcipotriol may enhance the effect of UVR to induce skin tumours.</p><p>&nbsp;</p><p>No carcinogenicity or photocarcinogenicity studies have been performed with betamethasone dipropionate.</p><p>&nbsp;</p><p>In local tolerability studies in rabbits, Daivobet gel caused mild to moderate skin irritation and a slight transient irritation of the eye.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Paraffin, liquid</p><p>Polyoxypropylene-15 stearyl ether</p><p>Castor oil,hydrogenated</p><p>Butylhydroxytoluene (E32 l)</p><p>All-rac-a-tocopherol</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>In the absence of compatibility studies, this medicinal product must not be mixed with other medicinal products</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                2 years.

After first opening: 3 months .
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Do not refrigerate. Keep the bottle in the outer carton in order to protect from light.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>High-density polyethylene bottles with low-density polyethylene nozzle and a high-density polyethylene screw cap. The bottles are placed in cartons.</p><p>Pack sizes: 15, 30 , 60 and 2 x 60 g. Not all pack sizes may be marketed .</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Any unused medicinal product or waste material should be disposed of in accordance with local requirements</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                LEO Pharma A/S 
Ballerup DK-2750
 Denmark
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                [To be completed nationally]
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>